Processa Pharmaceuticals, Inc.
PCSA
$0.39
$0.0723.27%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.24% | -0.94% | -11.00% | 11.95% | 31.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.19% | 1.33% | 10.74% | 58.00% | 13.54% |
| Operating Income | -28.19% | -1.33% | -10.74% | -58.00% | -13.54% |
| Income Before Tax | -30.68% | -3.96% | -13.46% | -62.57% | -15.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -30.68% | -3.96% | -13.46% | -62.57% | -15.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.68% | -3.96% | -13.46% | -62.57% | -15.22% |
| EBIT | -28.19% | -1.33% | -10.74% | -58.00% | -13.54% |
| EBITDA | -28.18% | -1.32% | -10.74% | -58.00% | -22.43% |
| EPS Basic | 74.96% | 73.09% | 54.47% | 33.00% | 47.98% |
| Normalized Basic EPS | 74.96% | 73.09% | 54.47% | 33.00% | 47.98% |
| EPS Diluted | 74.96% | 73.09% | 54.47% | 33.00% | 47.98% |
| Normalized Diluted EPS | 74.96% | 73.09% | 54.47% | 33.00% | 47.98% |
| Average Basic Shares Outstanding | 421.88% | 286.25% | 149.20% | 142.63% | 121.51% |
| Average Diluted Shares Outstanding | 421.88% | 286.25% | 149.20% | 142.63% | 121.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |